WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the presentations related to the Company’s technology portfolio to be made at the American Association for Cancer Research (AACR) annual meeting being held April 16-20, 2016 in New Orleans, LA.
